SNSE vs. NBRV, IMRX, XLO, LEXX, NXTC, UNCY, CARA, RMTI, HCWB, and EYEN
Should you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include Nabriva Therapeutics (NBRV), Immuneering (IMRX), Xilio Therapeutics (XLO), Lexaria Bioscience (LEXX), NextCure (NXTC), Unicycive Therapeutics (UNCY), Cara Therapeutics (CARA), Rockwell Medical (RMTI), HCW Biologics (HCWB), and Eyenovia (EYEN). These companies are all part of the "pharmaceutical preparations" industry.
Nabriva Therapeutics (NASDAQ:NBRV) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.
Nabriva Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.14, meaning that its share price is 86% less volatile than the S&P 500.
0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by company insiders. Comparatively, 25.5% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Sensei Biotherapeutics had 6 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 7 mentions for Sensei Biotherapeutics and 1 mentions for Nabriva Therapeutics. Nabriva Therapeutics' average media sentiment score of 0.07 beat Sensei Biotherapeutics' score of 0.00 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.
Sensei Biotherapeutics has a net margin of 0.00% compared to Sensei Biotherapeutics' net margin of -148.11%. Nabriva Therapeutics' return on equity of -46.67% beat Sensei Biotherapeutics' return on equity.
Sensei Biotherapeutics has lower revenue, but higher earnings than Nabriva Therapeutics. Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.
Nabriva Therapeutics received 370 more outperform votes than Sensei Biotherapeutics when rated by MarketBeat users. However, 76.67% of users gave Sensei Biotherapeutics an outperform vote while only 58.31% of users gave Nabriva Therapeutics an outperform vote.
Sensei Biotherapeutics has a consensus price target of $4.50, suggesting a potential upside of 183.02%.
Summary
Sensei Biotherapeutics beats Nabriva Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Sensei Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sensei Biotherapeutics Competitors List
Related Companies and Tools
